[Calcium antagonists for the treatment of Raynaud's phenomenon]. 1983

U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl

The effectiveness of a new, nifedipine-like calcium antagonist (Bay K 9320) on the severity and frequency of episodic digital vasospasms was studied in a randomized double-blind trial of 24 patients (10 women, 14 men) with Raynaud's phenomenon. During the winter months the patients took one tablet three times daily for three weeks, each tablet either containing 20 mg of the calcium antagonist or a placebo. Three patients had collagen disease, 21 a primary form of Raynaud's phenomenon. Subjective improvement was reported by nine of twelve patients receiving the drug, while no improvement occurred in nine patients on the placebo. Light-plethysmography demonstrated under calcium antagonist treatment a reduction in the cold-provoked acral blood flow decrease more than four-fold compared with the unchanged value in the placebo group.

UI MeSH Term Description Entries
D008297 Male Males
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011928 Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress. Cold Fingers, Hereditary,Raynaud Phenomenon,Raynaud's Disease,Raynauds Disease
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003258 Consumer Behavior Behavior associated with the procurement of goods, services, or experiences. Consumer Preference,Consumer Satisfaction,Behavior, Consumer,Behaviors, Consumer,Consumer Behaviors,Consumer Preferences,Preference, Consumer,Preferences, Consumer,Satisfaction, Consumer
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
January 1993, Therapie,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
November 1998, Current opinion in rheumatology,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
February 1985, The American journal of medicine,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
February 2016, The Cochrane database of systematic reviews,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
January 2014, The Cochrane database of systematic reviews,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
August 1984, Arthritis and rheumatism,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
November 1986, Ugeskrift for laeger,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
September 2006, Journal of the American Academy of Dermatology,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
January 1994, Clinics in dermatology,
U Müller-Bühl, and C Diehm, and W Scheuermann, and H Mörl
May 1986, The British journal of dermatology,
Copied contents to your clipboard!